Trial Profile
Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms CANONICAL Study
- 30 Mar 2021 Status changed from active, no longer recruiting to completed.
- 07 Oct 2019 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.
- 07 Oct 2019 Status changed from recruiting to active, no longer recruiting.